ATE336511T1 - Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren - Google Patents

Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren

Info

Publication number
ATE336511T1
ATE336511T1 AT96905369T AT96905369T ATE336511T1 AT E336511 T1 ATE336511 T1 AT E336511T1 AT 96905369 T AT96905369 T AT 96905369T AT 96905369 T AT96905369 T AT 96905369T AT E336511 T1 ATE336511 T1 AT E336511T1
Authority
AT
Austria
Prior art keywords
peptidomimetics
peptides
activate
function
structural similarity
Prior art date
Application number
AT96905369T
Other languages
English (en)
Inventor
Thanos Halazonetis
Wolfgang Hartwig
Original Assignee
Wistar Inst
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst, Bayer Corp filed Critical Wistar Inst
Application granted granted Critical
Publication of ATE336511T1 publication Critical patent/ATE336511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AT96905369T 1995-02-16 1996-02-16 Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren ATE336511T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/392,542 US6169073B1 (en) 1995-02-16 1995-02-16 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function

Publications (1)

Publication Number Publication Date
ATE336511T1 true ATE336511T1 (de) 2006-09-15

Family

ID=23550993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96905369T ATE336511T1 (de) 1995-02-16 1996-02-16 Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren

Country Status (10)

Country Link
US (6) US6169073B1 (de)
EP (1) EP0809655B1 (de)
JP (1) JP3980055B2 (de)
KR (1) KR100598744B1 (de)
AT (1) ATE336511T1 (de)
AU (1) AU718963B2 (de)
CA (1) CA2213229C (de)
DE (1) DE69636450T2 (de)
ES (1) ES2271950T3 (de)
WO (1) WO1996025434A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
GB9521544D0 (en) * 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
AU4394697A (en) * 1996-08-13 1998-03-06 Trustees Of Princeton University, The P53 mutant
EP0989136A4 (de) * 1997-05-15 2002-10-09 Kyowa Hakko Kogyo Kk Peptide mit zyklischen strukturen, die die aktivität von mutierten p53 proteinen wiederherstellen können.
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6767889B1 (en) * 1998-11-10 2004-07-27 Temple University Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
AU4486500A (en) * 1999-04-23 2000-11-10 Research Corporation Technologies, Inc. Therapeutic compositions and methods for treating tumors
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
GB0011439D0 (en) * 2000-05-12 2000-06-28 Novartis Res Found Cancer diagnosis and assays for screening
AU2001261697A1 (en) * 2000-05-16 2001-11-26 The Regents Of The University Of California Methods for identifying novel therapeutics and diagnostics in the p53 pathway
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6989239B2 (en) * 2001-06-20 2006-01-24 R.E.D. Laboratories, N.V./S.A. Methods for diagnosis and treatment of chronic immune diseases
US20050032060A1 (en) * 2001-08-31 2005-02-10 Shishir Shah Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
US20070105778A1 (en) 2002-01-23 2007-05-10 El-Gewely Mohamed R Methods of screening molecular libraries and active molecules identified thereby
US6916621B2 (en) * 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
WO2005002526A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
EP1648935A2 (de) 2003-07-25 2006-04-26 Amgen Inc. Antagonisten und agonisten von ldcam und anwendungsverfahren
US7109852B2 (en) * 2004-01-28 2006-09-19 Lear Corporation Vehicle occupancy intruder security system
WO2005074521A2 (en) * 2004-01-30 2005-08-18 The Trustees Of Columbia University In The City Of New York C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
WO2007149062A2 (en) * 2005-03-14 2007-12-27 Board Of Regents, The University Of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
KR100749858B1 (ko) * 2005-08-12 2007-08-16 연세대학교 산학협력단 ｐ53 변이체 및 그의 용도
WO2008064401A1 (en) * 2006-11-28 2008-06-05 Alzhyme Pty Ltd Improved peptide composition
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7960506B2 (en) * 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008104000A2 (en) * 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
EP2224961A1 (de) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen
EP2307456B1 (de) 2008-06-27 2014-10-15 Amgen Inc. Die inhibierung von ang-2 zur behandlung multipler sklerose
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2011038049A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
CN103118692A (zh) 2010-04-26 2013-05-22 Atyr医药公司 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
EP2566496B1 (de) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von methionyl-trna-synthetasen
ES2623805T3 (es) 2010-05-03 2017-07-12 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
EP3023496B1 (de) 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
KR20130099938A (ko) 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
AU2013221317B2 (en) 2012-02-16 2017-07-06 Pangu Biopharma Limited Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７のフラグメントおよびその使用
WO2015019318A1 (en) * 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants
EP3492106B1 (de) 2013-08-09 2021-02-17 Ardelyx, Inc. Verbindungen und verfahren zur hemmung eines phosphattransports
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
CN108884137B (zh) 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途
CN112236162A (zh) 2018-04-06 2021-01-15 昂科莱奇公司 用于裂解选择性癌细胞的组合物
WO2020023300A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies, Inc. Treatment of lymmphatic metastases
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20210345989A1 (en) 2018-10-04 2021-11-11 Koninklijke Philips N.V. Fluid flow detection for ultrasound imaging devices, systems, and methods
WO2021072056A1 (en) * 2019-10-08 2021-04-15 Portage Glasgow Limited P53 peptide disrupters of f0x04:p53 protein binding, variants and conjugates thereof.
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
WO2023060115A1 (en) * 2021-10-05 2023-04-13 The Penn State Research Foundation Methods for treating cancers with mutated p53

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362623A (en) 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US6051384A (en) 1992-09-30 2000-04-18 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Method of detecting p53-specific antibodies
FR2698367B1 (fr) 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
GB9224784D0 (en) 1992-11-26 1993-01-13 Univ Dundee Cellular protein
WO1995017213A1 (en) 1993-12-21 1995-06-29 Sloan-Kettering Institute For Cancer Research P53-based polypeptide fragments, nucleic acid molecules encoding same, and uses thereof
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function

Also Published As

Publication number Publication date
US6784157B2 (en) 2004-08-31
CA2213229A1 (en) 1996-08-22
US6420118B1 (en) 2002-07-16
US7666983B2 (en) 2010-02-23
US20030171537A1 (en) 2003-09-11
EP0809655B1 (de) 2006-08-16
EP0809655A1 (de) 1997-12-03
JPH11500311A (ja) 1999-01-12
DE69636450T2 (de) 2007-05-03
US6245886B1 (en) 2001-06-12
US20070167611A1 (en) 2007-07-19
US20030124557A1 (en) 2003-07-03
JP3980055B2 (ja) 2007-09-19
KR19980702283A (ko) 1998-07-15
AU718963B2 (en) 2000-05-04
KR100598744B1 (ko) 2006-09-22
ES2271950T3 (es) 2007-04-16
US7189801B2 (en) 2007-03-13
WO1996025434A1 (en) 1996-08-22
AU4915096A (en) 1996-09-04
US6169073B1 (en) 2001-01-02
DE69636450D1 (de) 2006-09-28
CA2213229C (en) 2014-10-14

Similar Documents

Publication Publication Date Title
ATE336511T1 (de) Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren
EP0832973A3 (de) GTP-bindende Proteine
GR3034332T3 (en) Protein purification.
BG103522A (en) Compositions and methods for ob type protein syntheses
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
ATE397062T1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
ES2172044T3 (es) Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina.
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
AU7216498A (en) Inhibitors of the urokinase receptor
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
EP0780472A3 (de) Stress Proteine
ATE103979T1 (de) Menschliches lymphotoxin.
WO1999031229A3 (en) Peptides and nucleic acids derived from eisenia foetida and the use thereof
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2002014348A3 (en) Glycoproteins and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties